Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKTOB vs AMIKIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Prevention of organ rejection in kidney, liver, and heart transplants,Rheumatoid arthritis,Psoriasis
Treatment of serious gram-negative bacterial infections,Infections caused by susceptible strains of Pseudomonas aeruginosa, Escherichia coli, Proteus, Klebsiella, Serratia, and Enterobacter
Adults: 10 mg orally once daily.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Terminal elimination half-life is 8-12 hours; prolonged in renal impairment (up to 20-30 hours in anuria).
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Hepatic via CYP3A4 enzyme system; major metabolites include AM1, AM9, and AM4N.
Amikacin is not metabolized; it is excreted unchanged primarily by glomerular filtration.
Renal: 70-80% unchanged; biliary/fecal: 10-15% as metabolites.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
20-30% primarily to albumin.
0-10% (low binding to albumin).
0.25-0.4 L/kg; indicates distribution primarily in extracellular fluid.
0.25 L/kg in adults; higher in neonates and edema states (0.3-0.4 L/kg), indicating distribution into extracellular fluid.
Intramuscular: approximately 90%; oral: not absorbed (0% due to degradation in GI tract).
IM: 100% (complete absorption); oral: <1% (not absorbed).
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min or dialysis: 2.5 mg once daily.
GFR 30-59 m L/min: extend dosing interval to every 12-24 hours; GFR 15-29 m L/min: extend to every 24-48 hours; GFR <15 m L/min: extend to every 48-72 hours or consider peritonitis dosing; adjust based on serum levels
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
No specific Child-Pugh based adjustments required; amikacin is minimally hepatically metabolized; monitor renal function as primary clearance route
Not established for children <18 years.
Neonates: 15-20 mg/kg/day IV/IM every 12-24 hours depending on gestational age; Infants and children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day
No specific dose adjustment; monitor for hypotension and renal function.
Start with lower initial doses based on renal function; monitor renal function and serum amikacin levels closely; usual initial dose reduction to 7.5 mg/kg every 12-24 hours based on estimated GFR
Increased risk of lymphomas and other malignancies, particularly of the skin. Increased susceptibility to infections. Cyclosporine can cause nephrotoxicity and hepatotoxicity.
Amikacin can cause nephrotoxicity and ototoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity (both vestibular and auditory) can occur in patients with pre-existing renal damage and in those with normal renal function treated with higher doses or for longer periods than recommended.
Nephrotoxicity, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, increased risk of infections and malignancies, anaphylaxis (IV formulation).
Neurotoxicity (ototoxicity) and nephrotoxicity; neuromuscular blockade; respiratory paralysis; cross-allergenicity among aminoglycosides; monitoring of renal function and drug levels recommended.
Hypersensitivity to cyclosporine or any component of the formulation, abnormal renal function, uncontrolled hypertension, malignancies, concurrent use with PUVA or UVB therapy in psoriasis.
Hypersensitivity to amikacin or any aminoglycoside; history of ototoxicity with prior aminoglycoside use.
No significant food interactions. Avoid alcohol while taking this medication.
No significant food interactions. Maintain adequate hydration. Avoid alcohol as it may worsen side effects.
First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; monitor for fetal growth restriction and oligohydramnios.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicity, ototoxicity) at doses similar to or lower than human doses. Amikacin crosses the placenta. First trimester: Risk cannot be excluded; use only if clearly needed. Second and third trimesters: Potential for fetal nephrotoxicity and ototoxicity; avoid use unless necessary for serious infections. Risk category D (positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience).
Not recommended during breastfeeding. M/P ratio unknown; potential infant exposure via milk.
Amikacin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.1-0.2. After intramuscular administration of 500 mg, peak milk concentrations are about 1-2 mcg/m L. Because of low oral bioavailability (poorly absorbed from the GI tract), systemic effects in the nursing infant are unlikely. However, theoretical risk of alteration of infant gut flora and direct exposure. Use with caution, especially in premature infants or those with renal impairment. The American Academy of Pediatrics considers amikacin compatible with breastfeeding.
No standard dose adjustment; increased clearance in pregnancy may require higher doses; therapeutic drug monitoring advised.
Pharmacokinetic changes during pregnancy (e.g., increased volume of distribution, increased renal clearance) may require dose adjustments, but specific guidelines are not established. Generally, standard dosing based on actual body weight and renal function is used. Therapeutic drug monitoring is recommended, especially in third trimester or with concurrent renal impairment. Dose adjustments should be based on serum levels to maintain therapeutic efficacy while minimizing toxicity. No dose reduction is universally recommended; individualize based on renal function and clinical response.
AKTOB is a beta-lactam antibiotic; monitor for hypersensitivity reactions, especially in patients with penicillin allergy. Adjust dose in renal impairment (Cr Cl <30 m L/min). Administer by slow IV infusion over 3-5 minutes or as directed. Observe for signs of Clostridioides difficile infection.
Monitor peak (20-30 mcg/m L) and trough (1-8 mcg/m L) serum levels; adjust dose based on renal function. Avoid concurrent use with other ototoxic/nephrotoxic drugs. Use extended-interval dosing (e.g., 15-20 mg/kg IV once daily) when possible. Assess for vestibular toxicity (ataxia, vertigo) and cochlear toxicity (tinnitus, high-frequency hearing loss).
Complete the full course of therapy even if symptoms improve.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,Inform your doctor if you have kidney problems or are on dialysis.,This medication may cause diarrhea; do not treat with anti-diarrheal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
Report any hearing loss, ringing in ears, dizziness, or unsteadiness immediately.,Drink plenty of fluids to help prevent kidney damage.,Avoid taking other aminoglycosides or strong diuretics unless prescribed.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKTOB vs AMIKIN, answered by our medical review team.
AKTOB is a Aminoglycoside Antibiotic (Ophthalmic) that works by Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.. AMIKIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKTOB and AMIKIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKTOB is: Adults: 10 mg orally once daily.. The standard adult dose of AMIKIN is: 15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKTOB and AMIKIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKTOB is classified as Category C. First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; m. AMIKIN is classified as Category C. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.